{"filing":{"accession_number":"0001193125-26-278533","cik":"0001783183","ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"d166684d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm"},"events":[{"id":13000,"run_id":11540,"accession_number":"0001193125-26-278533","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Phathom announced completion of enrollment in its Phase 2 pHalcon-EoE-201 clinical trial for VOQUEZNA in eosinophilic esophagitis, with 95 patients enrolled at 41 U.S. sites and topline results anticipated in Q4 2026. This is a material operational/clinical milestone for a biopharmaceutical company's drug development program, but does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named event types. The disclosure is material to investors assessing the company's pipeline progress and regulatory prospects.","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10014,"accession_number":"0001193125-26-278533","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Phathom announced completion of enrollment in its Phase 2 pHalcon-EoE-201 clinical trial for VOQUEZNA in eosinophilic esophagitis, with 95 patients enrolled at 41 U.S. sites and topline results anticipated in Q4 2026. This is a material operational/clinical milestone for a biopharmaceutical company's drug development program, but does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named event types. The disclosure is material to investors assessing the company's pipeline progress and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:00:37.258625+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10014,"accession_number":"0001193125-26-278533","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Phathom announced completion of enrollment in its Phase 2 pHalcon-EoE-201 clinical trial for VOQUEZNA in eosinophilic esophagitis, with 95 patients enrolled at 41 U.S. sites and topline results anticipated in Q4 2026. This is a material operational/clinical milestone for a biopharmaceutical company's drug development program, but does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named event types. The disclosure is material to investors assessing the company's pipeline progress and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:00:37.258625+00:00","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-06-23"}]}